Head & neck · 2025
Clinical Outcomes of Intensity Modulated Proton Therapy for Salivary Gland Carcinoma: High Local Control and Quality of Life Preservation.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Takano Gaku, Kawakita Daisuke, Iwata Hiromitsu, Hattori Yukiko, Nakajima Koichiro, Tsuzuki Yusuke, Sudo Shuou, Toshito Toshiyuki, Hayashi Kensuke, Matoba Takuma, Sawabe Michi, Minohara Kiyoshi, Iwaki Sho, Nakai Kazuyuki, Iwase Yu, Iwasaki Shinichi, Ogino Hiroyuki
Аннотация
BACKGROUND: In recent years, particle therapy has shown promise as a local treatment for salivary gland carcinoma (SGC); however, its efficacy and safety remain unclear. This study aimed to evaluate the clinical outcomes of intensity-modulated proton therapy (IMPT) for SGC.
METHODS: We performed a single-institution retrospective analysis of patients with SGC who underwent IMPT.
RESULTS: IMPT was performed on 28 SGC patients, of which 18 were for definitive treatment and 10 were for postoperative treatment. The 2-year overall survival (OS), progression-free survival (PFS), and local control (LC) rates for definitive treatment cases were 70.1%, 25.0%, and 82.5%, respectively. The 2-year OS, PFS, and LC rates for postoperative treatment cases were 100%, 80.0%, and 90.0%, respectively. Quality of life scores in the EORTC QLQ-C30 and QLQ-HN35 were preserved for 1 year after treatment.
CONCLUSIONS: Our study suggests the efficacy and safety of IMPT in SGC patients.
METHODS: We performed a single-institution retrospective analysis of patients with SGC who underwent IMPT.
RESULTS: IMPT was performed on 28 SGC patients, of which 18 were for definitive treatment and 10 were for postoperative treatment. The 2-year overall survival (OS), progression-free survival (PFS), and local control (LC) rates for definitive treatment cases were 70.1%, 25.0%, and 82.5%, respectively. The 2-year OS, PFS, and LC rates for postoperative treatment cases were 100%, 80.0%, and 90.0%, respectively. Quality of life scores in the EORTC QLQ-C30 and QLQ-HN35 were preserved for 1 year after treatment.
CONCLUSIONS: Our study suggests the efficacy and safety of IMPT in SGC patients.